Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and Internation Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT)
Authors
Keywords
-
Journal
LEUKEMIA
Volume 29, Issue 1, Pages 20-26
Publisher
Springer Nature
Online
2014-08-25
DOI
10.1038/leu.2014.250
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
- (2014) E. Rumi et al. BLOOD
- A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis
- (2014) C. L. Andersen et al. HAEMATOLOGICA
- The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients
- (2014) P Guglielmelli et al. LEUKEMIA
- Phase I/II adaptive design for drug combination oncology trials
- (2014) Nolan A. Wages et al. STATISTICS IN MEDICINE
- Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management
- (2013) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints
- (2013) T. Sugimoto et al. BIOSTATISTICS
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
- (2013) G. Barosi et al. BLOOD
- Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial
- (2013) H. Gisslinger et al. BLOOD
- Molecular Pathways: JAK/STAT Pathway: Mutations, Inhibitors, and Resistance
- (2013) A. Quintas-Cardama et al. CLINICAL CANCER RESEARCH
- Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study
- (2013) A Tefferi et al. LEUKEMIA
- Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells
- (2013) W. Fiskus et al. MOLECULAR CANCER THERAPEUTICS
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- mTOR Inhibitors Alone and in Combination with JAK2 Inhibitors Effectively Inhibit Cells of Myeloproliferative Neoplasms
- (2013) Costanza Bogani et al. PLoS One
- Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis
- (2013) Richard T Silver et al. Expert Review of Hematology
- Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)
- (2012) T. Barbui et al. BLOOD
- Model-based treatment optimization of a novel VEGFR inhibitor
- (2012) Ron J. Keizer et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Incidence, survival and prevalence of myeloid malignancies in Europe
- (2012) O. Visser et al. EUROPEAN JOURNAL OF CANCER
- Immunomodulatory agents in myelofibrosis
- (2012) Ali Tabarroki et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
- (2012) Robyn M. Emanuel et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
- (2012) Alfonso Quintás-Cardama et al. LEUKEMIA RESEARCH
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
- (2012) Roberto Marchioli et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
- (2012) Giovanni Barosi et al. PLoS One
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- New mutations and pathogenesis of myeloproliferative neoplasms
- (2011) W. Vainchenker et al. BLOOD
- Recombinant interferon- may retard progression of early primary myelofibrosis: a preliminary report
- (2011) R. T. Silver et al. BLOOD
- Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients
- (2011) A. Carobbio et al. BLOOD
- Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study
- (2011) Tiziano Barbui et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Polycythemia Vera With Hydroxyurea and Pipobroman: Final Results of a Randomized Trial Initiated in 1980
- (2011) Jean-Jacques Kiladjian et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM)
- (2010) S. Thepot et al. BLOOD
- Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency, and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cancer Institute Investigational Drug Steering Committee
- (2010) S. P. Ivy et al. CLINICAL CANCER RESEARCH
- DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
- (2010) Naseema Gangat et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders
- (2010) M. Pang et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- A phase-2 trial of low-dose pomalidomide in myelofibrosis
- (2010) K H Begna et al. LEUKEMIA
- What are RBC-transfusion-dependence and -independence?
- (2010) R.P. Gale et al. LEUKEMIA RESEARCH
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
- (2009) G. Barosi et al. BLOOD
- Thrombosis in primary myelofibrosis: incidence and risk factors
- (2009) T. Barbui et al. BLOOD
- A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
- (2009) F. Passamonti et al. BLOOD
- Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera
- (2008) J.-J. Kiladjian et al. BLOOD
- New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
- (2008) F. Cervantes et al. BLOOD
- Myelofibrosis with myeloid metaplasia: The advanced phase of an untreated disseminated hematological cancer
- (2008) Hans Carl Hasselbalch LEUKEMIA RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now